Probiodrug AG (Probiodrug), today announced that Dr.
Hendrik Liebers, Probiodrug's chief financial officer, will present
a corporate update at the annual BIO International Convention, being
held from the 23rd to the 26th of June 2014. Dr.
Liebers' presentation will take place at 11:15am on the 26th
of June in the Pacific Beach Room at the San Diego Convention Center.
The BIO International Convention is hosted by the Biotechnology Industry
Organization (BIO), which represents more than 1,100 biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations.The BIO International Convention is the largest global event
for the biotechnology industry and attracts the biggest names in
biotech, offers key networking and partnering opportunities, and
provides insights and inspiration on the major trends affecting the
industry. For more information on BIO and the BIO International
Convention, please visit http://convention.bio.org.
About Probiodrug AG
Probiodrug is a biopharmaceutical company dedicated to the discovery and
development of novel therapeutic solutions to treat people with
Alzheimer's disease. The Company has medical use and composition of
matter patents related to the inhibition of glutaminyl cyclase,
providing the Company with a dominant position in this field of
research. Probiodrug is backed by institutions such as BB Biotech,
Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM
Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group,
funds managed by Wellington Management and private investors.
Probiodrug's core capabilities are based on its long-standing expertise
in the elucidation of the structure and function of enzymes which play a
central role in the maturation of hormones. Probiodrug was founded in
1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more
information, please visit www.probiodrug.de.
[ Back To NFVZone's Homepage ]